BioCryst says Japan approves Orladeyo for pediatric HAE patients aged 2-11
BCRX•Launch timing and local marketing authorization
BioCryst said launch in Japan will follow National Health Insurance pricing.
OrphanPacific holds the Japan marketing authorization.
Japan clears Orladeyo for pediatric hereditary angioedema prevention
BioCryst said Japan’s Ministry of Health, Labour and Welfare has granted marketing clearance for once-daily Orladeyo to prevent hereditary angioedema attacks in children aged 2 to <12.
The approval broadens access in Japan to what BioCryst described as the first oral prophylactic option for this age group.
